AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30822515 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 0
Study 30822559 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PFASs (specifically perfluorooctanesulfonate and perfluoroundecanoic acid)
Number of subjects: 0
Study 30822559 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (Comparison)
Number of subjects: 0
Study 30823880 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Health Status Questionnaire (version 2)
Number of subjects: 258
Study 30823897 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided complete revascularization (CR)
Number of subjects: 1631
Study 30823897 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only revascularization (COR)
Number of subjects: 1631
Study 30824206 — intervention group
Group type: COMPARATOR
Intervention: Photobiomodulation treatment
Number of subjects: 0
Study 30824206 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study 30824558 — intervention group
Group type: EXPERIMENTAL
Intervention: CoRisk score (including copeptin levels, age, NIH Stroke Scale, and recanalization therapy)
Number of subjects: 1102
Study 30824558 — intervention group
Group type: COMPARATOR
Intervention: CoRisk score without copeptin
Number of subjects: 1102
Study 30824645 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 300
Study 30825104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib 600 mg/d
Number of subjects: 11
Study 30825104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib 1000 mg/d for 2 weeks, then 800 mg/d thereafter
Number of subjects: 11
Study 30825970 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent SBRT (40 Gy) and nelfinavir (1250 mg BID for 5 weeks)
Number of subjects: 46
Study 30826071 — intervention group
Group type: EXPERIMENTAL
Intervention: Deletion genotype (n = 37)
Number of subjects: 106
Study 30826071 — intervention group
Group type: COMPARATOR
Intervention: Nondeletion genotype (n = 21)
Number of subjects: 106
Study 30826071 — intervention group
Group type: EXPERIMENTAL
Intervention: Both genotypes
Number of subjects: 106
Study 30826192 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO stent
Number of subjects: 2614
Study 30826465 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib added to rituximab (R) plus BEAM regimen
Number of subjects: 0
Study 30826465 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (R) plus BEAM regimen without bortezomib
Number of subjects: 0
Study 30826528 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute culprit lesion (Group A)
Number of subjects: 159
Study 30826528 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable obstructive coronary disease (Group B)
Number of subjects: 159
Study 30826528 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obstructive or absent coronary disease (Group C)
Number of subjects: 159
Study 30826528 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission cTnI > 0.46 ng/mL with STEMI present in ECG
Number of subjects: 159
Study 30826767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-layer spectral detector CT (SDCT) including static stress CT perfusion (CTP)
Number of subjects: 75
Study 30826792 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAL-D culturally tailored diabetes self-management programme
Number of subjects: 0
Study 30826792 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 30826789 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP development
Number of subjects: 1250
Study 30826789 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status and cost of illness
Number of subjects: 1250
Study 30826789 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-adjusted life years (QALYs)
Number of subjects: 1250
Study 30827133 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (uncontrolled)
Number of subjects: 1673
Study 30827133 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (medically treated but uncontrolled)
Number of subjects: 1673
Study 30827133 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (treated and controlled)
Number of subjects: 1673
Study 30827133 — intervention group
Group type: COMPARATOR
Intervention: Normotension
Number of subjects: 1673
Study 30827193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 237
Study 30827933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating inflammatory cytokines (LDH, sIL-2R, TNF-α, decreased LMR)
Number of subjects: 228
Study 30827933 — intervention group
Group type: COMPARATOR
Intervention: International Prognostic Index (IPI)
Number of subjects: 228
Study 30827933 — intervention group
Group type: COMPARATOR
Intervention: NCCN-IPI
Number of subjects: 228
Study 30828313 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 Plasma Levels
Number of subjects: 0
Study 30828456 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial impression of the attending physician
Number of subjects: 0
Study 30828456 — intervention group
Group type: COMPARATOR
Intervention: Initial impression of the site investigator
Number of subjects: 0
Study 30829754 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (Bellafill)
Number of subjects: 42
Study 30829829 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning intervention
Number of subjects: 30
Study 30830538 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-sparing mastectomy (SSM)
Number of subjects: 160
Study 30830538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple-sparing mastectomy (NSM)
Number of subjects: 160
Study 30830538 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (SSM and NSM)
Number of subjects: 160
Study 30830886 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR)
Number of subjects: 0
Study 30830886 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (PNB)
Number of subjects: 0
Study 30831104 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion (days 1-7 from last menstrual period)
Number of subjects: 125
Study 30831104 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent hormonal contraceptive use
Number of subjects: 125
Study 30831104 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion
Number of subjects: 125
Study 30831104 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent contraceptive use
Number of subjects: 125
Study 30831104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 125
Study 30831104 — intervention group
Group type: COMPARATOR
Intervention: Late insertion (remainder of menstrual cycle)
Number of subjects: 125
Study 30832571 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage- and risk stratification scores, clinical impression scores, laboratory tests
Number of subjects: 0
Study 30832577 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically managed patients in a structured management program
Number of subjects: 186
Study 30832577 — intervention group
Group type: COMPARATOR
Intervention: Surgically treated patients
Number of subjects: 186
Study 30832606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg administered every 2 weeks up to 24 months or until confirmed progression or intolerable toxicity
Number of subjects: 22
Study 30832606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 22
Study 30832636 — intervention group
Group type: EXPERIMENTAL
Intervention: Persona Knee Implant System
Number of subjects: 146
Study 30832656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) for detection of intraplaque hemorrhage (IPH)
Number of subjects: 132
Study 30832656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced (DCE)-CMR for assessment of plaque microvasculature
Number of subjects: 132
Study 30832720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole, trimethoprim and guaifenesin (STG)
Number of subjects: 103
Study 30832732 — intervention group
Group type: EXPERIMENTAL
Intervention: α-PD-1 therapy
Number of subjects: 6
Study 30832732 — intervention group
Group type: EXPERIMENTAL
Intervention: α-TGFβ monotherapy
Number of subjects: 6
Study 30832732 — intervention group
Group type: EXPERIMENTAL
Intervention: α-PD-1 and α-TGFβ combinatorial therapy
Number of subjects: 6
Study 30832732 — intervention group
Group type: EXPERIMENTAL
Intervention: α-TGFβ antibody administration
Number of subjects: 6
Study 30833313 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of obesity, functional capacity and exercise capacity assessments, quality of life questionnaires, and blood and tissue sampling for biomarker analysis.
Number of subjects: 0
Study 30833313 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of interest focusing on metabolism (lipids, amino acids) and inflammation (adipokines, cytokines, and chemokines).
Number of subjects: 0
Study 30833368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1000
Study 30833370 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean glycemic exposure
Number of subjects: 0
Study 30833370 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and time-dependent glycemic and nonglycemic risk factors
Number of subjects: 0
Study 30833417 — intervention group
Group type: EXPERIMENTAL
Intervention: Biallelic mutations in base excision repair genes
Number of subjects: 1
Study 30833442 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin treatment with hypersensitivity reaction management
Number of subjects: 860
Study 30833442 — intervention group
Group type: COMPARATOR
Intervention: Non-hypersensitivity reaction group
Number of subjects: 860
Study 30833489 — intervention group
Group type: EXPERIMENTAL
Intervention: Merestinib (120 mg once daily)
Number of subjects: 186
Study 30833915 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Parent Training
Number of subjects: 0
Study 30833915 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30834280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (Progen) containing hydrolyzed collagen peptides, plasma proteins, hyaluronic acid-chondroitin sulfate complex, and vitamin C
Number of subjects: 72
Study 30834280 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (control group)
Number of subjects: 72
Study 30834940 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib 37.5 mg/day on a continuous daily dosing schedule
Number of subjects: 12
Study 30834972 — intervention group
Group type: EXPERIMENTAL
Intervention: SiCaP EP (Inductigraft™, Altapore) used as bone grafting material in PLF surgery
Number of subjects: 102
Study 30835255 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo synthesized neoantigen-loaded dendritic cell vaccines
Number of subjects: 6
Study 30835255 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared neoantigen peptide library
Number of subjects: 6
Study 30835255 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized immunotherapy
Number of subjects: 6
Study 30835533 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAIR index (AI-linked continuous glucose monitoring)
Number of subjects: 50
Study 30836314 — intervention group
Group type: EXPERIMENTAL
Intervention: Safingol
Number of subjects: 0
Study 30836314 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR)
Number of subjects: 0
Study 30836948 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre-dialysis serum magnesium concentration
Number of subjects: 66
Study 30836948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration > 2.5 mEq/L
Number of subjects: 66
Study 30836948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic volume and potassium removal
Number of subjects: 66
Study 30836948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous potassium and weight change
Number of subjects: 66
Study 30836953 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal management of six modifiable haemodialysis practices
Number of subjects: 0
Study 30836994 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacted individually
Number of subjects: 4065
Study 30836994 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacted face-to-face
Number of subjects: 4065
Study 30836994 — intervention group
Group type: EXPERIMENTAL
Intervention: Signed collaboration agreement
Number of subjects: 4065
Study 30836994 — intervention group
Group type: EXPERIMENTAL
Intervention: Completed baseline questionnaire
Number of subjects: 4065
Study 30836994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout rate
Number of subjects: 4065
Study 30837247 — intervention group
Group type: EXPERIMENTAL
Intervention: Overuse of medical interventions (commission errors) in primary care
Number of subjects: 0
Study 30837247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of overuse
Number of subjects: 0
Study 30837503 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus cisplatin (AP)
Number of subjects: 73
Study 30837503 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel plus gemcitabine (AG)
Number of subjects: 73
Study 30837835 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation
Number of subjects: 0
Study 30837835 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30838348 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in fermentable carbohydrates (FODMAPs)
Number of subjects: 197
Study 30838348 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet records for 4 consecutive days
Number of subjects: 197
Study 30839493 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hormone therapy (HT) prescriptions
Number of subjects: 116
Study 30839493 — intervention group
Group type: EXPERIMENTAL
Intervention: New prescriptions for systemic HT
Number of subjects: 116
Study 30839493 — intervention group
Group type: EXPERIMENTAL
Intervention: Renewal prescriptions for systemic HT
Number of subjects: 116
Study 30839493 — intervention group
Group type: EXPERIMENTAL
Intervention: Renewal prescriptions with conjugated equine estrogen doses ≥0.625 mg
Number of subjects: 116
Study 30839493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions for systemic estrogen in women with a uterus
Number of subjects: 116
Study 30840064 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFIRI
Number of subjects: 72
Study 30840064 — intervention group
Group type: COMPARATOR
Intervention: Wild-type patients (no mutations)
Number of subjects: 72
Study 30840064 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RAS (KRAS/NRAS) mutations
Number of subjects: 72
Study 30840064 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RAS/BRAF mutations
Number of subjects: 72
Study 30840757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (4000 units daily for 2 weeks)
Number of subjects: 85
Study 30840757 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85
Study 30840787 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg) for 8 weeks (Phase 1)
Number of subjects: 211
Study 30840787 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg) continued for responders, adjunctive aripiprazole (2-10 mg) for nonresponders for a further 8 weeks (Phase 2)
Number of subjects: 211
Study 30840787 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg)
Number of subjects: 211
Study 30840787 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAPS (Lam Employment Absence and Productivity Scale)
Number of subjects: 211
Study 30840787 — intervention group
Group type: EXPERIMENTAL
Intervention: Early symptomatic improvement
Number of subjects: 211
Study 30841510 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfat-PRP ATMP
Number of subjects: 3
Study 30842026 — intervention group
Group type: EXPERIMENTAL
Intervention: Race duration
Number of subjects: 1002
Study 30842026 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) at baseline
Number of subjects: 1002
Study 30842026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac TnI concentrations
Number of subjects: 1002
Study 30842026 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT concentrations
Number of subjects: 1002
Study 30842026 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI assay
Number of subjects: 1002
Study 30842026 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT assay
Number of subjects: 1002
Study 30842122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 30843005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-18-fluorodexoglucose quantification
Number of subjects: 123
Study 30843056 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Guideline (CDG) for influenza testing
Number of subjects: 1941
Study 30843056 — intervention group
Group type: EXPERIMENTAL
Intervention: CDG scoring system (score of ≥3 indicates testing warranted)
Number of subjects: 1941
Study 30843107 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased salt iodine concentration from 20 to 25 mg/kg
Number of subjects: 1447
Study 30843107 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous iodine concentration of 20 mg/kg)
Number of subjects: 1447
Study 30843160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily
Number of subjects: 21
Study 30843184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant (BMT) with post-transplant cyclophosphamide (PTCy)
Number of subjects: 10
Study 30843659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (5, 10, 15, or 20 mg BID for 3 weeks out of five for seven cycles) combined with Ibrutinib (420 mg daily)
Number of subjects: 12
Study 30844465 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter telomere length (TL)
Number of subjects: 195
Study 30844465 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalizing psychopathology at 8 to 10 years
Number of subjects: 195
Study 30845873 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Blockers
Number of subjects: 720
Study 30845873 — intervention group
Group type: COMPARATOR
Intervention: Persistent heart failure with reduced ejection fraction (HF r EF)
Number of subjects: 720
Study 30845873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- or high-dose β-blockers
Number of subjects: 720
Study 30845917 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 641
Study 30845934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower HDL-C levels
Number of subjects: 202
Study 30845934 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C levels in a single model
Number of subjects: 202
Study 30845934 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C levels with additional controls for cerebrovascular disease and coronary heart disease
Number of subjects: 202
Study 30845934 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated triglycerides (TG)
Number of subjects: 202
Study 30845934 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated triglycerides (TG) with remaining 4 MetS components
Number of subjects: 202
Study 30845934 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MetS and its components (obesity, reduced HDL-C, elevated glucose, elevated blood pressure)
Number of subjects: 202
Study 30845939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with 10 Gy prescribed at a 5-mm depth of the tumor bed
Number of subjects: 42
Study 30845938 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated panel of airway and blood-based molecular biomarkers
Number of subjects: 0
Study 30845938 — intervention group
Group type: EXPERIMENTAL
Intervention: Biospecimens including nasal brushings, serum, plasma, and intrathoracic airway samples
Number of subjects: 0
Study 30845960 — intervention group
Group type: EXPERIMENTAL
Intervention: EMONO
Number of subjects: 12
Study 30845970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) measurement
Number of subjects: 137
Study 30845970 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) increase
Number of subjects: 137
Study 30845970 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 137
Study 30845970 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (male vs female)
Number of subjects: 137
Study 30845997 — intervention group
Group type: EXPERIMENTAL
Intervention: Three servings (28.3 g each) of sun dried raisins daily for 14 days
Number of subjects: 13
Study 30846083 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcaval access using Amplatzer nitinol cardiac occluders
Number of subjects: 100
Study 30846089 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-coated balloon treatment
Number of subjects: 1535
Study 30846271 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG Positron Emission Tomography (PET)
Number of subjects: 0
Study 30846327 — intervention group
Group type: EXPERIMENTAL
Intervention: 16α-
Number of subjects: 93
Study 30846367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia Nervosa (BN) group
Number of subjects: 62
Study 30846367 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 62
Study 30846408 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 0
Study 30846408 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 0
Study 30846500 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous romiplostim (1-10 μg/kg targeting platelet counts of 50-200×10^9/L)
Number of subjects: 0
Study 30847861 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women
Number of subjects: 109
Study 30847861 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 109
Study 30847861 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women with WHR > 0.85
Number of subjects: 109
Study 30848549 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 64
Study 30848695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Dry Powder for Inhalation
Number of subjects: 0
Study 30849082 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced disposition index (DI)
Number of subjects: 26